Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.258 SEK | +3.61% | -0.77% | -4.80% |
02-28 | Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
02-20 | Xintela Names New Chief Scientific Officer | MT |
Business Summary
Number of employees: 21
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Stem Cell Therapies
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 67 | 08-12-31 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 12-12-31 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 17-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 20-12-31 |
Chairman | 67 | 10-12-31 | |
Director/Board Member | 64 | 21-12-31 | |
Director/Board Member | 61 | 20-12-31 | |
Director/Board Member | 62 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 567,006,473 | 177,368,068 ( 31.28 %) | 0 | 31.28 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. |
Biotechnology
|
Sector
1st Jan change | Capi. | |
---|---|---|
-4.80% | 13.05M | |
+28.96% | 49.18B | |
+1.34% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.95% | 26.09B | |
-22.06% | 18.71B | |
+7.88% | 13.26B | |
+32.35% | 12.32B | |
-0.19% | 11.99B |
- Stock Market
- Equities
- XINT Stock
- Company Xintela AB